Epicrispr Raises $90 Million for EPI-321 Pivotal Path
Epicrispr Biotechnologies closed an oversubscribed $90 million Series C co-led by Octagon Capital and Janus Henderson Investors. Proceeds are intended to advance EPI-321 toward pivotal development in facioscapulohumeral muscular dystrophy, expand the programmable epigenetic…
